Limits...
Infliximab therapy for moderately severe Crohn's disease and ulcerative colitis: a retrospective comparison over 6 years.

Alzafiri R, Holcroft CA, Malolepszy P, Cohen A, Szilagyi A - Clin Exp Gastroenterol (2011)

Bottom Line: Evaluation of long-term outcome of therapy for both diseases.Few serious side effects were noted.No important statistically significant differences in treatment patterns or outcome were observed between the groups.

View Article: PubMed Central - PubMed

Affiliation: Jewish General Hospital, Division of Gastroenterology, Department of Medicine, McGill University School of Medicine, Montreal, Quebec, Canada;

ABSTRACT

Background: Infliximab has shown benefit in Crohn's disease (CD) and ulcerative colitis (UC).

Objective: Evaluation of long-term outcome of therapy for both diseases.

Methods: We analyzed retrospectively patients treated at infusion centers from one institution. Demographic, laboratory parameters leading up to biologic therapy and the subsequent pattern of outcomes in either disease were established as a database. Initial failure, subsequent need to change therapy, or need to adjust therapy were evaluated. Kruskal-Wallis (nonparametric) tests to compare two groups and Kaplan-Meier survival curve analysis were used to compare outcomes.

Results: Over approximately 6 years, 71 CD and 26 UC patients received 999 and 215 infusions, respectively, for a median of 62 months. Of these, 17% for CD and 19% for UC patients were primary failures. Following the start of infliximab, 18% of CD and 11% of UC patients required stoppage and switching to another type of therapy. In either CD or UC patients, 54% or 62%, respectively, continued therapy without the need to change to other treatments. Few serious side effects were noted. No important statistically significant differences in treatment patterns or outcome were observed between the groups.

Discussion: Long-term treatment of both inflammatory bowel diseases reflects outcomes of clinical trials.

Conclusions: This study emphasizes similarities between CD and UC and reports therapeutic success for an extended time.

No MeSH data available.


Related in: MedlinePlus

Survival analysis CD (N = 24/52) and UC (N = 10/19) patients who developed Grade A failure and/or Grade B failure (need to alter frequency or dose of infliximab therapy). Only patients who did not have primary failure were included, and three patients were missing data.Abbreviations: CD, Crohn’s disease; UC, ulcerative colitis.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3108681&req=5

f4-ceg-4-009: Survival analysis CD (N = 24/52) and UC (N = 10/19) patients who developed Grade A failure and/or Grade B failure (need to alter frequency or dose of infliximab therapy). Only patients who did not have primary failure were included, and three patients were missing data.Abbreviations: CD, Crohn’s disease; UC, ulcerative colitis.

Mentions: Figure 4 shows survival analysis for any failure defined as either Grade A and/or Grade B (need to adjust therapy). The graph shows patients without primary failure and excludes three with missing data. Five patients (all CD) with Grade A failure also had preceding Grade B failure. There was no significant difference between the survival curves for CD and UC patients (log-rank P-value = 0.14).


Infliximab therapy for moderately severe Crohn's disease and ulcerative colitis: a retrospective comparison over 6 years.

Alzafiri R, Holcroft CA, Malolepszy P, Cohen A, Szilagyi A - Clin Exp Gastroenterol (2011)

Survival analysis CD (N = 24/52) and UC (N = 10/19) patients who developed Grade A failure and/or Grade B failure (need to alter frequency or dose of infliximab therapy). Only patients who did not have primary failure were included, and three patients were missing data.Abbreviations: CD, Crohn’s disease; UC, ulcerative colitis.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3108681&req=5

f4-ceg-4-009: Survival analysis CD (N = 24/52) and UC (N = 10/19) patients who developed Grade A failure and/or Grade B failure (need to alter frequency or dose of infliximab therapy). Only patients who did not have primary failure were included, and three patients were missing data.Abbreviations: CD, Crohn’s disease; UC, ulcerative colitis.
Mentions: Figure 4 shows survival analysis for any failure defined as either Grade A and/or Grade B (need to adjust therapy). The graph shows patients without primary failure and excludes three with missing data. Five patients (all CD) with Grade A failure also had preceding Grade B failure. There was no significant difference between the survival curves for CD and UC patients (log-rank P-value = 0.14).

Bottom Line: Evaluation of long-term outcome of therapy for both diseases.Few serious side effects were noted.No important statistically significant differences in treatment patterns or outcome were observed between the groups.

View Article: PubMed Central - PubMed

Affiliation: Jewish General Hospital, Division of Gastroenterology, Department of Medicine, McGill University School of Medicine, Montreal, Quebec, Canada;

ABSTRACT

Background: Infliximab has shown benefit in Crohn's disease (CD) and ulcerative colitis (UC).

Objective: Evaluation of long-term outcome of therapy for both diseases.

Methods: We analyzed retrospectively patients treated at infusion centers from one institution. Demographic, laboratory parameters leading up to biologic therapy and the subsequent pattern of outcomes in either disease were established as a database. Initial failure, subsequent need to change therapy, or need to adjust therapy were evaluated. Kruskal-Wallis (nonparametric) tests to compare two groups and Kaplan-Meier survival curve analysis were used to compare outcomes.

Results: Over approximately 6 years, 71 CD and 26 UC patients received 999 and 215 infusions, respectively, for a median of 62 months. Of these, 17% for CD and 19% for UC patients were primary failures. Following the start of infliximab, 18% of CD and 11% of UC patients required stoppage and switching to another type of therapy. In either CD or UC patients, 54% or 62%, respectively, continued therapy without the need to change to other treatments. Few serious side effects were noted. No important statistically significant differences in treatment patterns or outcome were observed between the groups.

Discussion: Long-term treatment of both inflammatory bowel diseases reflects outcomes of clinical trials.

Conclusions: This study emphasizes similarities between CD and UC and reports therapeutic success for an extended time.

No MeSH data available.


Related in: MedlinePlus